Doxycycline and Airway Inflammation in Chronic Obstructive Pulmonary Disease (COPD)
|ClinicalTrials.gov Identifier: NCT00857038|
Recruitment Status : Unknown
Verified March 2009 by Medical Center Alkmaar.
Recruitment status was: Not yet recruiting
First Posted : March 6, 2009
Last Update Posted : March 6, 2009
|Condition or disease||Intervention/treatment||Phase|
|Chronic Obstructive Pulmonary Disease Inflammation Pulmonary Emphysema||Drug: Doxycycline Drug: Placebo||Phase 4|
COPD is a disease characterized by chronic inflammation and irreversible airway obstruction. Chronic inflammation lead to degradation of extracellular matrix and hereby destruction of lung parenchyma. Tetracyclines are known for their anti-inflammatory properties in diseases such as rheumatoid arthritis.
To assess the effect of doxycycline on markers of neutrophilic inflammation and proteolytic activity in induced sputum of stable GOLD II and III COPD patients.
Thirty patients with stable GOLD II COPD.
Placebo versus doxycycline in randomised design.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Doxycycline and Airway Inflammation in COPD: A Randomised Placebo Controlled Trial Studying the Effects of Doxycycline on Airway Inflammation in Patients With Moderate and Severe Stable COPD.|
|Study Start Date :||April 2009|
|Estimated Primary Completion Date :||August 2009|
|Estimated Study Completion Date :||January 2010|
Doxycycline 100mg daily
Doxycycline tablets, 100mg daily
Placebo Comparator: 2
Placebo tablets 100mg
- myeloperoxidase in induced sputum [ Time Frame: 3 weeks ]
- MMP-8, MMP-9, IL-6 levels and differential cell counts in induced sputum. [ Time Frame: 3 weeks ]
- Lung function (FEV1) [ Time Frame: 3 weeks ]
- Symptom scores [ Time Frame: 3 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00857038
|Contact: Wim G Boersma, MDemail@example.com|
|Medical Center Alkmaar||Not yet recruiting|
|Alkmaar, Noord-Holland, Netherlands, 1815JD|
|Contact: Wim G Boersma, MD 0031725482750 firstname.lastname@example.org|